ClinicalTrials.gg
Active, not recruitingNCT05981092Updated Jun 12, 2026

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

An observational study in Cardiomyopathy, Dilated and Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM), sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
35
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.

Enrollment
16th of 20
35 · median 166
Started
2022
the only one that year
Observational
21 of 64
6 open now
Primary completion
2027-08
later than 6 of 19 live
Registered
51st of 64
by date
Lead sponsor
2 of 64
Alexion Pharmaceuticals, Inc.

Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 16th largest by enrollment of the 20 observational ones that give a count, is the only one that started in 2022, is one of 21 observational ones, reaches primary completion later than 6 of the 19 other live ones, and was the 51st registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Cardiomyopathy, Dilated with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the natural progression of DCM (dilated cardiomyopathy) caused by BAG3 gene mutations. DCM is a condition as the heart muscle is weakened and the heart becomes enlarged. This makes it hard for the heart to pump enough blood for the body.

The study is seeking up to about 35 participants who have:

  • BAG3 mutation (change in the gene) that causes or is likely to cause dilated cardiomyopathy
  • NYHA (New York Heart Association) Class I-IV at screening (Stage B-D)
  • Left Ventricular Ejection Fraction less than or equal to 50% (meaning reduced heart function)

All participants in this study will receive their usual treatment. The investigators will observe the natural progression of people who have BAG3 DCM. This will help the investigators better understand the disease and aid in future research.

Participants will take part in this study for three years. During this time, participants will visit the site at least 8 times (about every 3 months for the first year and annually during year 2 and three). Participants will undergo study procedures and give information about their health. These procedures will include a physical exam, cardiac magnetic resonance imaging, echocardiography, ECG monitoring, activity monitoring, cardiopulmonary exercise testing, and blood tests. Participants will answer questions about health and quality of life. The study team will also call participants about 1 time over the phone.

03

Conditions studied

  • Cardiomyopathy, Dilated
  • Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)

Keywords

  • BAG3
  • DCM
  • cardiomyopathy
  • dilated cardiomyopathy
  • heritable heart disease
  • heart disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

primary care clinic and referrals from primary care clinic to investigational sites

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented BAG3 mutation that causes or is likely to cause dilated cardiomyopathy
  • Heart failure Stage B-D, (NYHA) Class I-IV
  • ≤50% (i.e., Reduced Heart Function)

Exclusion criteria

Exclusion Criteria:

  • Acute decompensated heart failure within 1 month prior to enrollment.(such as hospitalization)
  • Any of the following within 3 months prior to screening: myocardial infarction (MI), cardiac surgical procedures (other than for pacemaker/ICD/CRT-defibrillator [CRT-D] implantation), acute coronary syndrome, or hospitalization for cardiac arrhythmia.
  • History of heart transplantation
  • \<30 mL/min/1.73 m2 (significantly impaired kidney function)
  • Noncardiac condition that limits lifespan to \<1 year.
  • Presence of other form(s) of cardiomyopathy contributing to heart failure
  • Previous administration with an drug within 30 days (or as determined by the local requirement).
  • No more than 3 first-degree members of the same family who are already participating in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
35 participants (actual)
Patient registry
No

Groups and cohorts

  • BAG3 DCM

    A single arm observational trial where all participants will undergo the same schedule of assessments.

06

What researchers measure

Primary outcomes

  1. Determine baseline of cardiac structure and function in BAG3 associated DCM.

    Baseline measures of left ventricular volumes at end systole and diastole using imaging at baseline.

    Time frame: Baseline

  2. Determine changes over time in cardiac structure and function in BAG3 associated DCM.

    Changes over time of left ventricular volumes at end systole and diastole using imaging over the course of 3 years follow up time.

    Time frame: 3 years

Secondary outcomes

  1. Change from Baseline in high sensitivity troponin I (hsTNI) levels

    HsTNI will be collected at baseline through 3 years to observe the natural history (baseline and variance) of the biomarker and the correlation of hsTNI to severity of clinical disease progression.

    Time frame: Baseline to year 3

  2. Change from Baseline in high sensitivity troponin T (hsTNT) levels

    HsTNT will be collected at baseline through 3 years to observe the natural history (baseline and variance) of the biomarker and the correlation of hsTNT to severity of clinical disease progression.

    Time frame: Baseline to year 3

  3. Change from Baseline in N-terminal Prohormone of Pro-Brain-Type Natriuretic peptide (NT-proBNP) levels

    NT-proBNP will be collected at baseline through 3 years to observe the natural history (baseline and variance) of the biomarker and the correlation of NT-proBNP to severity of clinical disease progression.

    Time frame: Baseline to year 3

  4. Change from baseline in Measures of Oxygen Capacity

    Measured via Cardio Pulmonary Exercise Testing (CPET).

    Time frame: Baseline to year 3

  5. Change from Baseline in Scores of Kansas City Cardiomyopathy Questionnaire (KCCQ) domains

    Time frame: Baseline to year 3

  6. Change from Baseline in Scores of Patient Global Impression of Severity (PGI-S)

    Time frame: Baseline to year 3

  7. Change from Baseline in Scores of Patient Global Impression of Change (PGI-C)

    Time frame: Baseline to year 3

  8. Define the rate of cardiac status changes over time.

    The frequency and rate of incidence of death, heart transplant, MCS, heart failure, hospitalization, appropriate implantable cardioverter defibrillator shock, or aborted SCD.

    Time frame: 3 years

07

Study locations

15 sites
  • Research Site
    Palo Alto, California 94305, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    The Bronx, New York 10467, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Amsterdam, Amsterdam 1105 AZ, Netherlands
  • Research Site
    Maastricht, Maastricht 6229 HX, Netherlands
  • Research Site
    Warsaw, Warszawa 04-628, Poland
  • Research Site
    A Coruña, A Coruna 15006, Spain
  • Research Site
    Madrid, Madrid 28041, Spain
  • Research Site
    Majadahonda, Madrid 28222, Spain
  • Research Site
    El Palmar, Murcia 30120, Spain
  • Research Site
    Harefield, London UB9 6JH, United Kingdom
  • Research Site
    London, London EC1A 7BE, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Aug 2027, 57 months after the start.

Of 51 observational studies under Cardiomyopathy, Dilated, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 101. This study's planned 57 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Aug 8, 2023
StartActual
Oct 14, 2022
Primary completionEst.
Aug 12, 2027
CompletionEst.
Aug 12, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05981092
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Oct 14, 2022
Primary completion
Aug 12, 2027 (estimated)
Completion
Aug 12, 2027 (estimated)
Last update
Jun 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion